Vitality Biopharma Begins Trading Under New Stock Symbol “VBIO”

LOS ANGELES, CA–Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that effective immediately, its common stock now trades on the over-the-counter market under the...

Vitality Biopharma Advances Cannabosides for Treatment of Inflammatory Bowel Disease

Novel Cannabinoid Pharmaceuticals Provide Targeted Delivery of Cannabinoids and Reduced Delivery of Psychoactive THC to the Brain LOS ANGELES, CA–Vitality Biopharma, Inc. (OTCQB: STVFD) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today...

Vitality Biopharma Name Change and Corporate Actions Receive Shareholder Approval

LOS ANGELES, CA–Vitality Biopharma, Inc. (OTCQB: STVF) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced shareholder approval and the effective date of a 1-for-10 reverse stock split and a concurrent name...

Vitality Biopharma to Present at LD Micro and BIO Conferences

LOS ANGELES, CA–Vitality Biopharma, Inc. (OTCQB: STVF), a company dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Company CEO Mr. Robert Brooke will be presenting and meeting with investors at the upcoming 2016 LD Micro Invitational...

Launch of Vitality Biopharma for Cannabinoid Prodrug Pharmaceutical Development

Company to Focus on Treatment of Serious Neurological and Inflammatory Conditions LOS ANGELES, CA–Stevia First Corp. (OTCQB: STVF) (the “Company”) is pleased to announce that it is changing its name to Vitality Biopharma, Inc. and that the Company will be dedicated to development of cannabinoid prodrug pharmaceuticals, and unlocking the power of cannabinoids for treatment...

Shareholder Letter

Dear Shareholder: As an early-stage company, we’ve made notable progress over the last 2-3 years, and throughout it all we’ve been looking for a catalyst that will take our company to the next level. In a fortuitous turn of events, and as part of our ongoing R&D efforts, we have made significant discoveries that we...